Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1391-1400

  Boyda, H N ^a   Procyshyn, R M ^a,b   Tse, L ^a   Wong, D ^a   Pang, C C ^a   Honer, W G ^a,b   Barr, A M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

Antipsychotic; Atypical; Chronic; Glucose intolerance; Insulin resistance; Metabolic; Olanzapine; Rat; Second generation

Indexed keywords

GLUCOSE; INSULIN; OLANZAPINE;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRUG SENSITIZATION; FEMALE; FOLLOW UP; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; BENZODIAZEPINES; BLOOD GLUCOSE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSE INTOLERANCE; INSULIN; INSULIN RESISTANCE; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84856078402     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.02.019     Document Type: Article

References (58)

1. V.L. Albaugh, C.R. Henry, N.T. Bello, A. Hajnal, S.L. Lynch, B. Halle, and C.J. Lynch Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents Obesity (Silver Spring) 14 2006 36 51 (Pubitemid 46214773)
2. D.B. Allison, J.W. Newcomer, A.L. Dunn, J.A. Blumenthal, A.N. Fabricatore, G.L. Daumit, M.B. Cope, W.T. Riley, B. Vreeland, J.R. Hibbeln, and J.E. Alpert Obesity among those with mental disorders: a National Institute of Mental Health meeting report Am. J. Prev. Med. 36 2009 341 350
3. A.A. Arjona, S.X. Zhang, B. Adamson, and R.J. Wurtman An animal model of antipsychotic-induced weight gain Behav. Brain Res. 152 2004 121 127 (Pubitemid 38597070)
4. M.B. Assie, E. Carilla-Durand, L. Bardin, M. Maraval, M. Aliaga, N. Malfetes, M. Barbara, and A. Newman-Tancredi The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063 Eur. J. Pharmacol. 592 2008 160 166
5. T. Baptista, E. Araujo de Baptista, N.M. Ying Kin, S. Beaulieu, D. Walker, R. Joober, J. Lalonde, and D. Richard Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance Brain Res. 957 2002 144 151 (Pubitemid 35346582)
6. A.M. Barr, K.N. Fish, A. Markou, and W.G. Honer Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins Eur. J. Neurosci. 27 2008 2568 2574 (Pubitemid 351781674)
7. A.M. Barr, C.E. Young, K. Sawada, W.S. Trimble, A.G. Phillips, and W.G. Honer Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia Eur. J. Neurosci. 20 2004 303 307 (Pubitemid 38932150)
8. H.N. Boyda, L. Tse, R.M. Procyshyn, W.G. Honer, and A.M. Barr Preclinical models of antipsychotic drug-induced metabolic side effects Trends Pharmacol. Sci. 31 2010 484 497
9. H.N. Boyda, L. Tse, R.M. Procyshyn, D. Wong, T.K. Wu, C.C. Pang, and A.M. Barr A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 945 954
10. A.F. Chintoh, S.W. Mann, L. Lam, A. Giacca, P. Fletcher, J. Nobrega, and G. Remington Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model Schizophr. Res. 108 2009 127 133
11. A.F. Chintoh, S.W. Mann, L. Lam, C. Lam, T.A. Cohn, P.J. Fletcher, J.N. Nobrega, A. Giacca, and G. Remington Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration J. Clin. Psychopharmacol. 28 2008 494 499
12. A.F. Chintoh, S.W. Mann, T.K. Lam, A. Giacca, and G. Remington Insulin resistance following continuous, chronic olanzapine treatment: an animal model Schizophr. Res. 104 2008 23 30
13. C.C. Chiu, C.H. Chen, B.Y. Chen, S.H. Yu, and M.L. Lu The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 866 870
14. S. Choi, B. DiSilvio, J. Unangst, and J.D. Fernstrom Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats Life Sci. 81 2007 1024 1030 (Pubitemid 47384786)
15. G.D. Cooper, L.C. Pickavance, J.P. Wilding, J.C. Halford, and A.J. Goudie A parametric analysis of olanzapine-induced weight gain in female rats Psychopharmacology (Berl.) 181 2005 80 89 (Pubitemid 41440918)
16. G.D. Cooper, L.C. Pickavance, J.P. Wilding, J.A. Harrold, J.C. Halford, and A.J. Goudie Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities J. Psychopharmacol. 21 2007 405 413 (Pubitemid 47077303)
17. S.S. Evers, F. Calcagnoli, G. van Dijk, and A.J. Scheurink Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats Pharmacol. Biochem. Behav. 97 2010 163 169
18. M.J. Fell, N. Anjum, K. Dickinson, K.M. Marshall, L.M. Peltola, S. Vickers, S. Cheetham, and J.C. Neill The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats Psychopharmacology (Berl.) 194 2007 221 231 (Pubitemid 47457949)
19. M.J. Fell, J.C. Neill, N. Anjum, L.M. Peltola, and K.M. Marshall Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats J. Psychopharmacol. 22 2008 182 186 (Pubitemid 351322855)
20. M.J. Fell, J.C. Neill, and K.M. Marshall Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats Eur. Neuropsychopharmacol. 14 2004 385 392 (Pubitemid 39141681)
21. M.J. Fell, J.C. Neill, C. Rao, and K.M. Marshall Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats Psychopharmacology (Berl.) 182 2005 499 507 (Pubitemid 41464631)
22. G. Foussias, and G. Remington Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making Can. J. Psychiatry 55 2010 117 125
23. M.A. Geyer, K. Krebs-Thomson, D.L. Braff, and N.R. Swerdlow Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review Psychopharmacology (Berl.) 156 2001 117 154 (Pubitemid 32702206)
24. A.J. Goudie, J.A. Smith, and J.C. Halford Characterization of olanzapine-induced weight gain in rats J. Psychopharmacol. 16 2002 291 296 (Pubitemid 35470572)
25. M. Han, C. Deng, T.H. Burne, K.A. Newell, and X.F. Huang Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression Psychoneuroendocrinology 33 2008 569 580
26. M. Hasnain, S.K. Fredrickson, W.V. Vieweg, and A.K. Pandurangi Metabolic syndrome associated with schizophrenia and atypical antipsychotics Curr. Diab. Rep. 10 2010 209 216
27. D.W. Haupt, L.C. Rosenblatt, E. Kim, R.A. Baker, R. Whitehead, and J.W. Newcomer Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents Am. J. Psychiatry 166 2009 345 353
28. A. Hem, A.J. Smith, and P. Solberg Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink Lab. Anim. 32 1998 364 368 (Pubitemid 28482470)
29. W.G. Honer, R. Procyshyn, E.Y. Chen, G.W. Macewan, and A.M. Barr A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy J. Psychiatry Neurosci. 34 2009
30. W.G. Honer, A.E. Thornton, M. Sherwood, G.W. MacEwan, T.S. Ehmann, R. Williams, L.C. Kopala, R. Procyshyn, and A.M. Barr Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia CNS Drugs 21 2007 699 714 (Pubitemid 47294717)
31. K.L. Houseknecht, A.S. Robertson, W. Zavadoski, E.M. Gibbs, D.E. Johnson, and H. Rollema Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects Neuropsychopharmacology 32 2007 289 297 (Pubitemid 46106936)
32. M. Kalinichev, C. Rourke, A.J. Daniels, M.K. Grizzle, C.S. Britt, D.M. Ignar, and D.N. Jones Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats Psychopharmacology (Berl.) 182 2005 220 231 (Pubitemid 41464615)
33. M. Kalinichev, C. Rourke, and D.N. Jones Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine Behav. Pharmacol. 17 2006 289 292
34. J.M. Kane, O. Osuntokun, L.A. Kryzhanovskaya, W. Xu, V.L. Stauffer, S.B. Watson, and A. Breier A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia J. Clin. Psychiatry 70 2009 572 581
35. S. Kapur, S.C. VanderSpek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy J. Pharmacol. Exp. Ther. 305 2003 625 631 (Pubitemid 36459179)
36. L.V. Kessing, A.F. Thomsen, U.B. Mogensen, and P.K. Andersen Treatment with antipsychotics and the risk of diabetes in clinical practice Br. J. Psychiatry 197 2010 266 271
37. J.A. Lieberman, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, R.S. Keefe, S.M. Davis, C.E. Davis, B.D. Lebowitz, J. Severe, and J.K. Hsiao Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N. Engl. J. Med. 353 2005 1209 1223 (Pubitemid 41345943)
38. K. Lykkegaard, P.J. Larsen, N. Vrang, C. Bock, T. Bock, and L.B. Knudsen The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance Schizophr. Res. 103 2008 94 103
39. J.M. Meyer, V.G. Davis, D.C. Goff, J.P. McEvoy, H.A. Nasrallah, S.M. Davis, R.A. Rosenheck, G.L. Daumit, J. Hsiao, M.S. Swartz, T.S. Stroup, and J.A. Lieberman Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 Schizophr. Res. 101 2008 273 286
40. L.U. Monzillo, and O. Hamdy Evaluation of insulin sensitivity in clinical practice and in research settings Nutr. Rev. 61 2003 397 412 (Pubitemid 38140057)
41. R. Muniyappa, S. Lee, H. Chen, and M.J. Quon Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage Am. J. Physiol. Endocrinol. Metab. 294 2008 E15 E26
42. J.W. Newcomer Antipsychotic medications: metabolic and cardiovascular risk J. Clin. Psychiatry 68 Suppl. 4 2007 8 13 (Pubitemid 46762118)
43. S. Park, S.M. Hong, J.E. Lee, and S.R. Sung Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects Life Sci. 80 2007 2428 2435 (Pubitemid 46839073)
44. B.M. Patil, N.M. Kulkarni, and B.S. Unger Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain Eur. J. Pharmacol. 551 2006 112 115 (Pubitemid 44649297)
45. B. Pouzet, T. Mow, M. Kreilgaard, and S. Velschow Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human Pharmacol. Biochem. Behav. 75 2003 133 140 (Pubitemid 36577588)
46. R.M. Procyshyn, A.M. Barr, T. Brickell, and W.G. Honer Medication errors in psychiatry: a comprehensive review CNS Drugs 24 2010 595 609
47. R.M. Procyshyn, W.G. Honer, T.K. Wu, R.W. Ko, S.A. McIsaac, A.H. Young, J.L. Johnson, and A.M. Barr Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients J. Clin. Psychiatry 71 2010 566 573
48. R.M. Procyshyn, K.M. Wasan, A.E. Thornton, A.M. Barr, E.Y. Chen, E. Pomarol-Clotet, E. Stip, R. Williams, G.W. Macewan, C.L. Birmingham, and W.G. Honer Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment J. Psychiatry Neurosci. 32 2007 331 338 (Pubitemid 47492758)
49. G. Remington, and S. Kapur Antipsychotic dosing: how much but also how often? Schizophr. Bull. 36 2010 900 903
50. G. Remington, P. Seeman, A. Feingold, S. Mann, C. Shammi, and S. Kapur "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial J. Clin. Psychiatry 2010
51. C. Rummel-Kluge, K. Komossa, S. Schwarz, H. Hunger, F. Schmid, W. Kissling, J.M. Davis, and S. Leucht Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons Schizophr. Bull 2010
52. C. Rummel-Kluge, K. Komossa, S. Schwarz, H. Hunger, F. Schmid, C.A. Lobos, W. Kissling, J.M. Davis, and S. Leucht Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Schizophr. Res 2010
53. A.N. Samaha, P. Seeman, J. Stewart, H. Rajabi, and S. Kapur "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time J. Neurosci. 27 2007 2979 2986 (Pubitemid 46438984)
54. G.C. Smith, C. Chaussade, M. Vickers, J. Jensen, and P.R. Shepherd Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat Diabetologia 51 2008 2309 2317
55. G.C. Smith, M.H. Vickers, E. Cognard, and P.R. Shepherd Clozapine and quetiapine acutely reduce glucagon-like peptide-1 p.oduction and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour Schizophr. Res. 115 2009 30 40
56. L. Urichuk, T.I. Prior, S. Dursun, and G. Baker Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions Curr. Drug Metab. 9 2008 410 418 (Pubitemid 352025195)
57. E.M. van der Zwaal, M.C. Luijendijk, S.S. Evers, S.E. la Fleur, and R.A. Adan Olanzapine affects locomotor activity and meal size in male rats Pharmacol. Biochem. Behav. 97 2010 130 137
58. S. Weinbrenner, H.J. Assion, T. Stargardt, R. Busse, G. Juckel, and C.A. Gericke Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund Pharmacopsychiatry 42 2009 66 71